LOS ANGELES, May 09, 2019 (GLOBE NEWSWIRE) -- The Global Joint Pain Injections Market is estimated to grow at CAGR above 8 % over the forecast time frame 2019-2026 and reach the market value around USD 5.7 billion by 2026.

The global market is expected to expand between 2019 and 2026 to include an increase in the number of geriatric patients, an increase in awareness of joint disorders and high medical demands. Increasing the prevalence of joint pain amongst the population, demand for better treatment and development of healthcare infrastructure in various countries around the globe are expected to expand on the joint pain injection market.

Free Download Sample Report Pages for Better understanding@

Increased Obesity Rate Resulting In Joint Pain

The risk of obesity for various joint disorders, particularly knee-related, including knee pain and knee osteoarthritis is considerable. World obesity has tripled since 1975, according to a fact sheet published by the WHO. 2016. 2016. Overweight was 1.9 billion, with over 650 million adults being obese. In addition, in 2016, around 41 million children under 5 years of age were obese. National Health and Nutrition Survey (NHANES) 2015-2016 indicates more than 1 in four kids aged between 2 and 19 years had obesity, and about 47 percent of adults had obesity. Increasing patient pool is estimated to increase healthcare spending in developing countries and developed countries on joint pain therapy and, in consequence, to promote the injections market for common pain.

Market Snapshots

Arthritis is the leading cause of disability in U.S. adults according to the facts published by Arthritis Foundation. About 54 million adults and 300,000 children and babies in the United States suffer from arthritis or rheumatic conditions. By 2040, more than 78 million people in the United States are likely to have arthritis diagnosed by doctors. In addition, the most common type of arthritis is osteoarthritis and affects some 31 million people in the United States. More and more arthritis increases the demand for disease-modifying treatments which are expected to propel joint pain injections during the forecast period.

View Detail Information with Complete TOC@

The most common cause of joint pain and major disability and mobility among the population is arthritis. arthritis Current treatment options are not adequate as they are mainly aimed at relieving symptoms and mitigating pain. No drugs, such as osteoarthritis, are possible to cure, reverse or stop disease progression. Some patients are also incapable of finding relief by the treatments available and continue to suffer from pain. Hence, patients with joint pain have a large unmet need. This offers the chance for advance treatment options on the market for joint pain injections.

Hyaluronic acid injections are a highly attractive segment of the global pain injection market, followed by corticosteroid injections and other segments in terms of the injection type. This is due to the efficacy of hyaluronic acid injections in treating knee arthritis, which are contraindicated for other treatments. Viscosupplementation with hyaluronic acid in adults with knee osteoarthritis in the area of improved knee pain and function with minimal adverse effects accordingly is superior to intra-articular placebo and other traditional medicine, such as non-steroidal anti-inflammatory medicine(NSAID) published by CADTH.

Browse All official Market Research Reports Press Releases@

Explore Our Market Blog@ https://www.acumenresearchandconsulting.com/blogs

Regional Stance

Due to a large pool of patients, increased geriatric populations, increased obesity and high acceptance of the region's advanced treatments for pain alleviation, North America dominated the worldwide joint injection market. During the forecast period, the region is estimated to remain dominant. U.S. FDA approved for the treatment of the knee arthritis viscosis supplementation with hyaluronic acid products. In the next few years, increasing healthcare expenses and investment are also key to boosting the joint pain injection market. The Asia-Pacific joint pain injection market is expected to expand with a major CAGR as join disorders are increased in developing countries and research initiatives are ongoing, and hyaluronic acid products will be manufactured in Japan.

Key Players & Strategies

Allergan Plc., Pfizer Inc., Sanofi, Ferring, B, Flexion Therapeutics, Inc.., Anika Therapeutics, Inc., SEIKAGAKU CORPORATION, and Chugai Pharmaceutical Co., Ltd. are major actors operating on the common pain injections market. Inc. Key players expand their product portfolio by combining, acquiring and cooperating with leading medical firms that are expected to improve the availability of the products and thus boost the market.


The report is readily available and can be dispatched immediately after payment confirmation.

Buy this premium research report -

Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157

For Latest Update Follow Us:




Browse More Press Releases: http://www.amecoresearch.com/press-releases